Aprea Therapeutics, Inc.
APRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781983
No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.07M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Aprea Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +5 vs. Q1 2026
- Shares held
- 2.58M
- +332.3K (+14.8%) vs. Q1 2026
- Total value
- $2.07M
- +$355.0K (+20.7%) vs. Q1 2026
- New holders
- 7
- 6 more added
- Sold out
- 2
- 5 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APRE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $2.07M |
| Q1 2026 | 22 | $1.71M |
| Q4 2025 | 22 | $1.45M |
| Q3 2025 | 23 | $2.39M |
| Q2 2025 | 23 | $3.07M |
| Q1 2025 | 26 | $3.78M |
| Q4 2024 | 26 | $6.83M |
| Q3 2024 | 22 | $5.88M |
| Q2 2024 | 28 | $9.32M |
| Q1 2024 | 24 | $11.1M |
| Q4 2023 | 20 | $4.44M |
| Q3 2023 | 21 | $3.66M |
| Q2 2023 | 19 | $2.78M |
| Q1 2023 | 18 | $3.77M |
| Q4 2022 | 25 | $521.3K |
| Q3 2022 | 27 | $1.12M |
| Q2 2022 | 34 | $1.52M |
| Q1 2022 | 40 | $4.50M |
| Q4 2021 | 41 | $10.6M |
| Q3 2021 | 39 | $25.6M |
| Q2 2021 | 50 | $31.9M |
| Q1 2021 | 67 | $45.4M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Aprea Therapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 1,015,541 | $814.8K | 0.07% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 411,520 | $330.2K | 0.01% | +205,760+100.0% | Added |
| Vestal Point Capital, LP | 350,000 | $280.8K | 0.01% | 00.0% | Unchanged |
| Sphera Funds Management Ltd. | 270,000 | $216.6K | 0.03% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 105,800 | $84.9K | 0.00% | +80,700+321.5% | Added |
| Geode Capital Management, LLC | 74,869 | $60.1K | 0.00% | −44,262−37.2% | Reduced |
| Citadel Advisors LLC | 58,600 | $47.0K | 0.00% | +58,600 | New |
| BNP Paribas Arbitrage, SA | 45,211 | $36.3K | 0.00% | +5,394+13.5% | Added |
| Diadema Partners LP | 44,907 | $36.0K | 0.01% | +44,907 | New |
| Vanguard Fiduciary Trust Co | 38,464 | $30.8K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 34,939 | $28.0K | 0.00% | +21,921+168.4% | Added |
| Morgan Stanley | 25,830 | $20.7K | 0.00% | +3,500+15.7% | Added |
| Vanguard Capital Management LLC | 22,882 | $18.4K | 0.00% | +3,260+16.6% | Added |
| LPL Financial LLC | 16,052 | $12.9K | 0.00% | −5,000−23.8% | Reduced |
| HighTower Advisors, LLC | 13,864 | $11.1K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 13,705 | $11.0K | 0.00% | +13,705 | New |
| Persistent Asset Partners Ltd | 11,490 | $9.22K | 0.00% | +11,490 | New |
| XTX Topco Ltd | 10,565 | $8.48K | 0.00% | +10,565 | New |
| BlackRock, Inc. | 7,173 | $5.75K | 0.00% | −1,331−15.7% | Reduced |
| Tower Research Capital LLC (TRC) | 3,590 | $2.88K | 0.00% | −1,537−30.0% | Reduced |
| Group One Trading, L.P. | 577 | $463 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 473 | $379 | 0.00% | +473 | New |
| Advisor Group Holdings, Inc. | 295 | $236 | 0.00% | 00.0% | Unchanged |
| WealthCollab, LLC | 158 | $127 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 45 | $36 | 0.00% | +45 | New |
| SBI Securities Co., Ltd. | 16 | $13 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3 | $2 | 0.00% | −2,150−99.9% | Reduced |
| Scientech Research LLC | 0 | $0 | 0.00% | −60,281−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −13,500−100.0% | Sold out |